Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis by Patel, SM, Kang, YM, Im, K, Neuen, BL, Anker, SD, Bhatt, DL, Butler, J, Cherney, DZI, Claggett, BL, Fletcher, RA, Herrington, WG, Inzucchi, SE, Jardine, MJ, Mahaffey, KW, McGuire, DK, McMurray, JJV, Neal, B, Packer, M, Perkovic, V, Solomon, SD, Staplin, N, Vaduganathan, M, Wanner, C, Wheeler, DC, Zannad, F, Zhao, Y, Heerspink, HJL, Sabatine, MS, Wiviott, SD

Long-term effects of empagliflozin in patients with chronic kidney disease by Herrington, WG, Staplin, N, Agrawal, N, Wanner, C, Green, JB, Hauske, SJ, Emberson, JR, Preiss, D, Judge, P, Zhu, D, Dayanandan, R, Arimoto, R, Mayne, KJ, Ng, SYA, Sammons, E, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Liu, W, Kadowaki, T, Nangaku, M, Levin, A, Cherney, DZI, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Massey, D, Brueckmann, M, Landray, MJ, Baigent, C, Haynes, R